Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02924376 · ClinicalTrials.gov registry record · Phase 2

Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

A Phase 2 study of Cholangiocarcinoma, sponsored by Incyte Corporation.

Completed
Registry status
Phase 2
Development phase
147
Enrollment target
20
Study locations

NCT02924376 is a Phase 2 study of Cholangiocarcinoma that has completed, run by Incyte Corporation. The registered enrollment target is 147 participants, below the 383-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02924376, a Phase 2 study of Cholangiocarcinoma, has completed, sponsored by Incyte Corporation.

COMPLETED
Registry status
Phase 2
Development phase
147 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is evaluate the efficacy of pemigatinib in subjects with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 translocation who have failed at least 1 previous treatment.

Conditions Studied

Cholangiocarcinoma

Interventions

  • DRUG Pemigatinib

Study Locations (20)

Arizona

  • - Phoenix
  • - Tempe
  • - Tucson

California

  • - Orange
  • - San Francisco

Colorado

  • - Aurora
  • - Denver

Florida

  • - Gainesville
  • - Miami Beach

Illinois

  • - Chicago
  • - Evanston

Alaska

  • - Anchorage

Connecticut

  • - New Haven

Delaware

  • - Newark

Trial Details

FieldValue
Enrollment Target 147 participants
Start Date 2017-01-16
Est. Completion 2022-02-01
Phase Phase 2

Sponsor

Incyte Corporation

239 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02924376

The ClinicalTrials.gov registry entry for NCT02924376 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 147 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 383-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target (62% lower). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cholangiocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Pemigatinib is the first listed.

NCT02924376 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Arizona, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT02924376 about?

NCT02924376 is a clinical study titled "Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)". The purpose of this study is evaluate the efficacy of pemigatinib in subjects with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 translocation who have failed at least 1 previous treatment.

What is the current status of trial NCT02924376?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 147 participants. The study started on 2017-01-16. Estimated completion is 2022-02-01.

What conditions does trial NCT02924376 study?

This clinical trial studies the following conditions: Cholangiocarcinoma.

What interventions are being tested in trial NCT02924376?

The interventions under investigation include: Pemigatinib (DRUG).

Who is sponsoring clinical trial NCT02924376?

This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02924376 being conducted?

This trial has 20 study locations across Alaska, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cholangiocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cholangiocarcinoma

All registered trials for this condition

Alaska

All trials with a study site in Alaska

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.